Skip to main content

Tweets

SLE Prospect. Observational Study of 826 SLE pts over 3 yr for outcomes& IFN signature (IFNGS). 71% were IFNGS-high. IFNGS-high pts were younger. on GC w/ Hi SLEDAI-2K. SLEDAI-2K decreased over time, regardless of IFNGS. By 36mos, 45% had ≥1 flare; higher in IFNGS. https://t.co/c3zHT2GfR5
Dr. John Cush @RheumNow ( View Tweet )
13 hours 20 minutes ago
IL-1 Inhibition in CPPD Controlled clinical trials in patients with calcium Pyrophosphate Deposition Disease (CPPD) are scant. Now a metanalysis provides evidence that anakinra, an interleukin-1 inhibitor, is a promising alternative for patients with acute CPPD flares. https://t.co/7RkE2i6sYY
Dr. John Cush @RheumNow ( View Tweet )
14 hours 50 minutes ago
DAHLIAS study - Nipocalimab in Sjögren's Disease Nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG and autoantibodies, was shown to be effective in a phase 2 trial in patients with severe Sjögren's disease. https://t.co/tpoh8YF0F1 https://t.co/jFB1RKOqDV
Dr. John Cush @RheumNow ( View Tweet )
17 hours 20 minutes ago
Robinson et al has published that Epstein-Barr virus infects and reprograms autoreactive B cells to drive the systemic autoimmune response in SLE https://t.co/vjpvILrJOt https://t.co/HepyZrYW5L
Dr. John Cush @RheumNow ( View Tweet )
18 hours 1 minute ago
Mesothelin as a biomarker and potential therapeutic target in rheumatoid arthritis? Mesothelin is elevated in RA & animal models & promothes osteoclast differentiation & bony destruction. Blocking mesothelin has the potential to reduce bone destruction. https://t.co/WRXG91AqmJ https://t.co/hMgddPXhxG
Dr. John Cush @RheumNow ( View Tweet )
18 hours 4 minutes ago
Day 2 Recap: #ACR25 Highlights Join RheumNow Faculty Drs. David Liew, Antoni Chan, Mrinalini Dey, and Jack Cush as they discuss highlights and key takeaways from the Day 2 Recap. https://t.co/aBxLuDhIMC https://t.co/q75eHf45Gt
Dr. John Cush @RheumNow ( View Tweet )
18 hours 20 minutes ago
Putting Steroid Tapering into Practice in SLE Drs. Yuz Yusof and Ed Vital discuss abstract 1526 (Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project) presented at #ACR25. https://t.co/TtDC1pnaJr
Dr. John Cush @RheumNow ( View Tweet )
19 hours 20 minutes ago
CAR-T Therapy: Where is it Heading? Dr. Peter Nash summarizes several abstracts looking at CAR-T therapy from #ACR25. https://t.co/bC8p1LnZMW https://t.co/KKn3jjsBW0
Dr. John Cush @RheumNow ( View Tweet )
20 hours 20 minutes ago
Deep Learning Model Accurately Detects Ankylosing Spondylitis on MRI AI continues to move from research labs into rheumatology clinics, promising to reshape how inflammatory diseases are diagnosed and monitored. AS, in particular, poses a diagnostic challenge—its early imaging https://t.co/TH2YIiPPEq
Dr. John Cush @RheumNow ( View Tweet )
21 hours 20 minutes ago
Western Australia study of 1854 SLE pts (median 40 yrs old). Interstitial lung disease was seen in in 3.8% of SLE, 26 fold more than controls. Risk factors for ILD included older age, smoking and serositis. SLE-ILD pts had higher mortality rates (MR 52.0, CI 37.0–71.1).

Dr. John Cush @RheumNow ( View Tweet )

21 hours 50 minutes ago
Sjögren's disease RCTs: Has the Long Drought Ended? At #ACR25, two late breaking abstracts have triggered hope for patients suffering from Sjögren's disease. https://t.co/nNNx5sXzCz https://t.co/r9VBgyYgOC
Dr. John Cush @RheumNow ( View Tweet )
23 hours 19 minutes ago
PRED-SAFE: Shared Decision-Making Tool for Chronic Prednisone Use Drs. Jiha Lee and Shivani Garg discuss abstract 1052 (“Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic https://t.co/ZBH61Uzzc8
Dr. John Cush @RheumNow ( View Tweet )
1 day 12 hours ago
×